Jason O'Byrne
CIK: 0001871145
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 1, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
650K shares- - Mar 20, 2026VIR
Vir Biotechnology, Inc.
Other(J)Direct2.5K shares- - Mar 20, 2026VIR
Vir Biotechnology, Inc.
Other(J)Indirect2.5K shares- - Feb 24, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct1.6K shares at avg. $9.53$16K - Feb 23, 2026VIR
Vir Biotechnology, Inc.
Sale(S)Direct2.1K shares at avg. $7.45$16K - Feb 22, 2026VIR
Vir Biotechnology, Inc.
Award(A)Direct55K shares- - Nov 17, 2025VIR
Vir Biotechnology, Inc.
Sale(S)Direct6.8K shares at avg. $5.56$38K - Feb 22, 2025VIR
Vir Biotechnology, Inc.
Award(A)Direct40K shares- - Nov 15, 2024VIR
Vir Biotechnology, Inc.
Award(A)Direct75K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 650,000 | - | - | Direct |
| Mar 20, 2026 |  VIR Vir Biotechnology, Inc. | Other(J) | 2,500 | - | $0 | Direct |
| Mar 20, 2026 | VIR Vir Biotechnology, Inc. | Other(J) | 2,500 | - | $0 | Indirect |
| Feb 24, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 1,634 | $9.53 | $15,576 | Direct |
| Feb 23, 2026 | VIR Vir Biotechnology, Inc. | Sale(S) | 2,089 | $7.45 | $15,569 | Direct |
| Feb 22, 2026 | VIR Vir Biotechnology, Inc. | Award(A) | 55,000 | - | $0 | Direct |
| Nov 17, 2025 | VIR Vir Biotechnology, Inc. | Sale(S) | 6,799 | $5.56 | $37,782 | Direct |
| Feb 22, 2025 | VIR Vir Biotechnology, Inc. | Award(A) | 40,000 | - | - | Direct |
| Nov 15, 2024 | VIR Vir Biotechnology, Inc. | Award(A) | 75,000 | - | $0 | Direct |
1-9 of 9 transactions
About O'Byrne Jason
O'Byrne Jason (SEC CIK 0001871145) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Olema Pharmaceuticals, Inc. (OLMA) and EVP & Chief Financial Officer of Vir Biotechnology, Inc. (VIR).
Signal8 holds 9 ownership filings by O'Byrne Jason (2 Form 3, 7 Form 4), filed between Oct 3, 2024 and Sep 2, 2026. Those filings report 9 transactions, from Nov 15, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on O'Byrne Jason's filings is in SAN FRANCISCO, CA.
Recent filings by O'Byrne Jason
- Sep 1, 2026: Grant or award of OLMA derivative securities (Form 4, code A).
- Mar 20, 2026: Other transactions of VIR shares (2 lines, Form 4, code J).
- Feb 24, 2026: Open-market sale of VIR shares (Form 4, code S).
- Feb 23, 2026: Open-market sale of VIR shares (Form 4, code S).
- Feb 22, 2026: Grant or award of VIR shares (Form 4, code A).
Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)
- Harmon Cyrus, Director
- BVF PARTNERS L P/IL, Director
- BUTITTA CYNTHIA M, Director
- Garland J. Scott, Director
- Hrustanovic Gorjan, Director
- CLARK IAN T, Director